138 related articles for article (PubMed ID: 17522242)
1. Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations.
Jeung HC; Rha SY; Kim HK; Lim HY; Kim S; Kim SY; Gong SJ; Park CH; Ahn JB; Noh SH; Chung HC
Oncologist; 2007 May; 12(5):543-54. PubMed ID: 17522242
[TBL] [Abstract][Full Text] [Related]
2. Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer.
Jeung HC; Rha SY; Park CH; Im CK; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Int J Oncol; 2009 Mar; 34(3):787-96. PubMed ID: 19212683
[TBL] [Abstract][Full Text] [Related]
3. Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m2 bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Ahn JB; Noh SH; Roh JK; Chung HC
Jpn J Clin Oncol; 2010 Jan; 40(1):29-35. PubMed ID: 19880858
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of S-1 as first-line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncology Group study.
Koizumi W; Akiya T; Sato A; Sakuyama T; Sasaki E; Tomidokoro T; Hamada T; Fujimori M; Kikuchi Y; Shimada K; Mine T; Yamaguchi K; Sasaki T; Kurihara M
Cancer Chemother Pharmacol; 2010 May; 65(6):1093-9. PubMed ID: 19727730
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
7. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan.
Chen JS; Chao Y; Hsieh RK; Cheng AL; Chen PM; Chiou TJ; Chao TY; Yeh KH; Chen LT; Whang-Peng J
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1281-9. PubMed ID: 20714726
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Narahara H; Iishi H; Imamura H; Tsuburaya A; Chin K; Imamoto H; Esaki T; Furukawa H; Hamada C; Sakata Y
Gastric Cancer; 2011 Mar; 14(1):72-80. PubMed ID: 21340666
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Tsushima T; Hironaka S; Boku N; Machida N; Yamazaki K; Yasui H; Taku K; Fukutomi A; Onozawa Y
Gastric Cancer; 2010 Nov; 13(4):245-50. PubMed ID: 21128060
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.
Koizumi W; Kurihara M; Nakano S; Hasegawa K
Oncology; 2000 Apr; 58(3):191-7. PubMed ID: 10765119
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
Blum M; Suzuki A; Ajani JA
Future Oncol; 2011 Jun; 7(6):715-26. PubMed ID: 21675835
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey.
Kawai H; Ohtsu A; Boku N; Hamamoto Y; Nagashima F; Muto M; Sano Y; Mera K; Yano T; Doi T; Yoshida S
Gastric Cancer; 2003; 6 Suppl 1():19-23. PubMed ID: 12775015
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
16. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
17. An early phase II study of S-1 in patients with metastatic pancreatic cancer.
Ueno H; Okusaka T; Ikeda M; Takezako Y; Morizane C
Oncology; 2005; 68(2-3):171-8. PubMed ID: 16006754
[TBL] [Abstract][Full Text] [Related]
18. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients.
Ichikawa W; Sasaki Y
Int J Clin Oncol; 2008 Jun; 13(3):206-11. PubMed ID: 18553229
[TBL] [Abstract][Full Text] [Related]
19. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
Yonemori K; Shimada Y; Goto A; Ura T; Arai T; Hamaguchi T; Muro K; Yamada Y; Shirao K
Gastric Cancer; 2004; 7(4):204-10. PubMed ID: 15616768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
